Key features and details
- Endogenous ionotropic / nicotinic antagonist
- CAS Number: 492-27-3
- Soluble in 1 eq. NaOH to 100 mM and in DMSO to 50 mM
- Form / State: Solid
- Source: Synthetic
Product nameKynurenic acid, endogenous ionotropic / nicotinic antagonist
DescriptionEndogenous ionotropic / nicotinic antagonist
Endogenous antagonist at ionotropic, glycine β and α7 nicotinic receptors. Neuroprotective in vivo. Water-soluble form available - please see Kynurenic acid sodium salt (ab120256)
Chemical name4-Hydroxyquinoline-2-carboxylic acid
Storage instructionsStore at Room Temperature. The product can be stored for up to 12 months.
Solubility overviewSoluble in 1 eq. NaOH to 100 mM and in DMSO to 50 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
- Epigenetics and Nuclear Signaling
- Domain Families
- HLH / Leucine Zipper
- Receptors & Transporters
- Broad spectrum / non-selective
2D chemical structure image of ab120064, Kynurenic acid, endogenous ionotropic / nicotinic antagonist
C1 and C2 - Inhibition of climbing fiber to Purkinje cell EPSCs in (control; black) by 1 mM Kynurenic acid (red, ab120064) or 100 nM NBQX (green, ab120045) recorded in 2.5 mM external Ca2+ at 0.05 Hz (C1) and 2 Hz (C2) stimulation frequency. D - Summary of inhibition of EPSCs by 1 mM Kynurenic acid (red, ab120064) and 100 nM NBQX (green, ab120045) in 2.5 mM external Ca2+.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab120064 has been referenced in 27 publications.
- Barnes JL et al. Developmentally Transient CB1Rs on Cerebellar Afferents Suppress Afferent Input, Downstream Synaptic Excitation, and Signaling to Migrating Neurons. J Neurosci 40:6133-6145 (2020). PubMed: 32631938
- Heubl M et al. GABAA receptor dependent synaptic inhibition rapidly tunes KCC2 activity via the Cl--sensitive WNK1 kinase. Nat Commun 8:1776 (2017). PubMed: 29176664
- Hiu T et al. Enhanced phasic GABA inhibition during the repair phase of stroke: a novel therapeutic target. Brain 139:468-80 (2016). PubMed: 26685158
- Zarnowska ED et al. Etomidate blocks LTP and impairs learning but does not enhance tonic inhibition in mice carrying the N265M point mutation in the beta3 subunit of the GABA(A) receptor. Neuropharmacology 93:171-178 (2015). PubMed: 25680234
- Shin JH et al. Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. Proc Natl Acad Sci U S A 112:8124-9 (2015). PubMed: 26080439